Aliases & Classifications for Conjunctival Disease

MalaCards integrated aliases for Conjunctival Disease:

Name: Conjunctival Disease 12 15
Conjunctival Diseases 56 45 74
Conjunctival Disorder 17

Classifications:



External Ids:

Disease Ontology 12 DOID:4251
ICD9CM 36 372 372.9
MeSH 45 D003229
NCIt 51 C27605
SNOMED-CT 69 59698003
ICD10 34 H10-H11 H11.9
UMLS 74 C0009759

Summaries for Conjunctival Disease

MalaCards based summary : Conjunctival Disease, also known as conjunctival diseases, is related to conjunctivitis and dermatitis, and has symptoms including visual disturbance and eye manifestations. An important gene associated with Conjunctival Disease is IL4 (Interleukin 4), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Histamine and Alcaftadine have been mentioned in the context of this disorder. Affiliated tissues include eye, testes and skin, and related phenotypes are hematopoietic system and digestive/alimentary

Wikipedia : 77 The conjunctiva is a tissue that lines the inside of the eyelids and covers the sclera (the white of the... more...

Related Diseases for Conjunctival Disease

Diseases related to Conjunctival Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 117)
# Related Disease Score Top Affiliating Genes
1 conjunctivitis 29.5 CCL11 HRH1 IL13 IL4 IL5 MS4A2
2 dermatitis 29.4 CCL11 IL13 IL4 IL5
3 dermatitis, atopic 28.2 CCL11 HRH1 IL13 IL4 IL5 MS4A2
4 parasitic ichthyosporea infectious disease 10.4 IL4 RHNO1
5 papillary conjunctivitis 10.4 CCL11 IL4
6 rhinosporidiosis 10.4 IL4 RHNO1
7 st. louis encephalitis 10.4 IFNA2 RNASE3
8 giant hemangioma 10.4 IFNA2 PLG
9 maxillary sinusitis 10.4 RHNO1 RNASE3
10 acute conjunctivitis 10.3 PLD3 PSEN2
11 acute hemorrhagic conjunctivitis 10.3 PLD3 PSEN2
12 orbital plasma cell granuloma 10.3 IFNA2 MRAP
13 iritis 10.3 MRAP PSEN2
14 penicillin allergy 10.3 IL13 IL4
15 toxocariasis 10.3 MRAP RNASE3
16 ascaridiasis 10.3 IL13 PLG
17 beta-lactam allergy 10.3 IL13 IL4
18 shipyard eye 10.3 PLD3 PSEN2
19 scleritis 10.3 IL4 IL5
20 blood group, globoside system 10.3 MRAP PLG
21 erysipeloid 10.3 NLRP3 PLG
22 egg allergy 10.3 IL4 IL5
23 loeffler endocarditis 10.3 IL5 RNASE3
24 sulfamethoxazole allergy 10.3 IL4 IL5
25 chronic orbital inflammation 10.3 IFNA2 MRAP
26 blepharoconjunctivitis 10.2 CCL11 IL4 RNASE3
27 pemphigoid gestationis 10.2 CCL11 IL5
28 giant papillary conjunctivitis 10.2 CCL11 IL4 RNASE3
29 trichinosis 10.2 IL4 IL5
30 anterior cranial fossa meningioma 10.2 PLG RHNO1
31 cold urticaria 10.2 NLRP3 RNASE3
32 cytokine deficiency 10.2 IL13 IL5
33 cow milk allergy 10.2 IL5 RNASE3
34 otitis media 10.2 CCL11 IL4 RNASE3
35 gaucher disease, type ii 10.2 IL4 IL5
36 angioimmunoblastic lymphadenopathy with dysproteinemia 10.2 IL13 IL5
37 respiratory syncytial virus infectious disease 10.2 IL13 IL5
38 bone inflammation disease 10.2 IL4 MRAP NLRP3
39 non-suppurative otitis media 10.2 IL4 IL5
40 cough variant asthma 10.2 IL4 IL5 RNASE3
41 atopic keratoconjunctivitis 10.2 IL4 IL5 RNASE3
42 intrinsic asthma 10.2 IL4 IL5 RNASE3
43 milk allergy 10.1 IL4 IL5 RNASE3
44 folliculitis 10.1 CCL11 IL4 IL5
45 endophthalmitis 10.1 MRAP PLG
46 nickel allergic contact dermatitis 10.1 IL13 IL4 IL5
47 filarial elephantiasis 10.1 IL4 IL5
48 apple allergy 10.1 IL13 IL4 IL5
49 intestinal schistosomiasis 10.1 IL13 IL4 IL5
50 chronic tic disorder 10.1 IL13 IL4 IL5

Graphical network of the top 20 diseases related to Conjunctival Disease:



Diseases related to Conjunctival Disease

Symptoms & Phenotypes for Conjunctival Disease

UMLS symptoms related to Conjunctival Disease:


visual disturbance, eye manifestations

MGI Mouse Phenotypes related to Conjunctival Disease:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.9 CCL11 HRH1 IL13 IL4 IL5 IL6ST
2 digestive/alimentary MP:0005381 9.8 IL13 IL4 IL5 IL6ST NLRP3 PLG
3 immune system MP:0005387 9.65 CCL11 HRH1 IL13 IL4 IL5 IL6ST
4 liver/biliary system MP:0005370 9.1 HRH1 IL4 IL5 IL6ST NLRP3 PLG

Drugs & Therapeutics for Conjunctival Disease

Drugs for Conjunctival Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 402)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-45-6 774
2
Alcaftadine Approved Phase 4,Phase 3 147084-10-4 19371515
3
Ephedrine Approved Phase 4,Phase 3,Phase 2 299-42-3 9294
4
Pheniramine Approved Phase 4 86-21-5 4761
5
Pseudoephedrine Approved Phase 4,Phase 3,Phase 2 90-82-4 7028
6
Naphazoline Approved, Investigational Phase 4,Phase 3 835-31-4 4436
7
Bepotastine Approved Phase 4,Phase 3,Phase 2 190786-44-8, 125602-71-3 2350
8
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2 302-25-0
9
Loteprednol Approved, Experimental Phase 4,Phase 3,Phase 2,Not Applicable 82034-46-6, 129260-79-3 9865442 444025
10
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-24-8 5755
11
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2 2921-57-5
12
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 83-43-2 6741
13
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 104987-11-3 6473866 445643 439492
14
Tocopherol Approved, Investigational Phase 4,Not Applicable 1406-66-2 14986
15
Povidone Approved Phase 4,Phase 3,Not Applicable 9003-39-8
16
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
17
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9004-61-9 53477741
18
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 216974-75-3
19
Tobramycin Approved, Investigational Phase 4,Phase 3,Not Applicable 32986-56-4 36294 5496
20
Norgestimate Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 35189-28-7 6540478
21
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 2,Not Applicable 57-63-6 5991
22
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-28-2 5757
23
Polyestradiol phosphate Approved Phase 4,Phase 3,Phase 2,Not Applicable 28014-46-2
24
Moxifloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 354812-41-2, 151096-09-2 152946
25
Polymyxin B Approved, Vet_approved Phase 4,Phase 3,Not Applicable 1404-26-8
26
Dipivefrin Approved Phase 4,Phase 3,Phase 2,Phase 1 52365-63-6 3105
27
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-02-2 5743
28
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 1177-87-3
29
Ganciclovir Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 82410-32-0 3454
30
Glycerol Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 56-81-5 753
31
Gatifloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 112811-59-3 5379
32
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 7440-66-6 32051
33
Ethanol Approved Phase 4,Phase 2,Not Applicable 64-17-5 702
34
Ofloxacin Approved Phase 4,Phase 3,Phase 2,Phase 1 82419-36-1 4583
35
Levofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 100986-85-4 149096
36
Fluorometholone Approved, Investigational Phase 4,Phase 3,Not Applicable 426-13-1 9878
37
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
38
Epinastine Approved, Investigational Phase 4,Phase 3 80012-43-7 3241
39
Fluticasone Approved, Experimental Phase 4,Phase 3,Phase 2 90566-53-3 62924
40
Desloratadine Approved, Investigational Phase 4,Phase 3 100643-71-8 124087
41
Ketotifen Approved Phase 4,Phase 3,Phase 2,Phase 1 34580-14-8, 34580-13-7 3827
42
Lifitegrast Approved Phase 4,Phase 3,Phase 2,Not Applicable 1025967-78-5
43
Azithromycin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83905-01-5 447043 55185
44
Ketorolac Approved Phase 4,Phase 2,Phase 3 74103-06-3, 66635-83-4 3826
45
Iodine Approved, Investigational Phase 4,Phase 3,Not Applicable 7553-56-2 807
46
Povidone-iodine Approved Phase 4,Phase 3,Not Applicable 25655-41-8
47
Menthol Approved Phase 4 2216-51-5 16666
48
Isotretinoin Approved Phase 4 4759-48-2 5282379 5538
49
Dimenhydrinate Approved Phase 4,Not Applicable 523-87-5 441281
50
Sorbitol Approved Phase 4 50-70-4 5780

Interventional clinical trials:

(show top 50) (show all 987)
# Name Status NCT ID Phase Drugs
1 Pterygium Head Body MMC1: Two Different Surgical Procedures and Their Effect on Endothelial Cell Count. Unknown status NCT02641132 Phase 4 Mitomycin C 0.02%
2 Ocular Allergy Treatment Practical Impact Trial Unknown status NCT01808768 Phase 4 Alcaftadine
3 Comparison of Tolerability Between Two Allergy Drops Unknown status NCT01390961 Phase 4 alacaftadine and naphazoline HCl & pheniramine maleate
4 The Effect of BEPREVE 1.5% on Tear Film Osmolarity and Tear Film Lipid Layer Unknown status NCT01346371 Phase 4 Bepreve (bepotastine ophthalmic solution) 1.5%
5 Use of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% for Allergic Conjunctivitis and Contact Lenses Unknown status NCT01337557 Phase 4 Bepotastine
6 A Study to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5% Unknown status NCT01437982 Phase 4 Loteprednol Etabonate;Prednisolone Acetate 1% Oph Susp
7 Topical Tacrolimus in Vernal Keratoconjunctivitis Unknown status NCT02456025 Phase 4 Topical tacrolimus
8 Effect of Intense Pulse Light (IPL) Treatment on Tear Film Osmolarity Unknown status NCT02992535 Phase 4
9 Oral Nutrition Impact on Tear Film Unknown status NCT01561040 Phase 4
10 Efficacy of FreshKote and Systane for the Treatment of Dry Eye and Improvement of Osmolarity Unknown status NCT01386073 Phase 4 FreshKote;Systane
11 Altaire Gel Forming Solution Versus Refresh Tears for the Treatment of Dry Eye Signs and Symptoms Unknown status NCT01382810 Phase 4 Altaire Gel forming solution;Refresh Tears
12 Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Unknown status NCT00704275 Phase 4 0.05% cyclosporin eye drop
13 0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients Unknown status NCT02595606 Phase 4 0.3% Sodium Hyaluronate
14 Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus Unknown status NCT00797030 Phase 4 cyclosporine and sodium carboximethycellulose;sodium carboximethycellulose
15 Role of Sub-Conjunctival Bevacizumab in Post Pterygium Excision Management Completed NCT01736449 Phase 4 Bevacizumab
16 Safety and Efficacy of Zylet vs Lotemax, Tobramycin and Vehicle in Pediatric Blepharoconjunctivitis Completed NCT00705159 Phase 4 loteprednol etabonate and tobramycin;loteprednol etabonate;Tobramycin;Vehicle of Zylet
17 Moxifloxacin vs. Polytrim for Conjunctivitis Completed NCT00581542 Phase 4 moxifloxacin;polytrim
18 Efficacy of Topical Cyclosporine 0.05% in the Prevention of Ocular Surface Inflammation Secondary to Pterygia Completed NCT00383396 Phase 4 Topical Cyclosporine
19 Non-Pharmaceutical Treatment of Seasonal Allergic Conjunctivitis Completed NCT01569191 Phase 4 Anti-allergic Medication
20 A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft as Measured by In-Vivo Confocal Microscopy Completed NCT02308501 Phase 4 Lastacaft ®;Tears Naturale ®
21 Effectiveness of Olopatadine HCl Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in Japan Completed NCT02251613 Phase 4 Olopatadine HCl ophthalmic solution, 0.1%;Epinastine HCl ophthalmic solution, 0.05%
22 A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis Completed NCT01732757 Phase 4 Alcaftadine 0.25%;Olopatadine 0.2%;dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
23 Evaluation of Prednisolone in a Modified Conjunctival Allergen Challenge Model Completed NCT01730872 Phase 4 Prednisolone Sodium Phosphate Ophthalmic Solution 1%;Tears Naturale II Ophthalmic Solution
24 Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients Completed NCT01697969 Phase 4 Olopatadine hydrochloride ophthalmic solution, 0.2%
25 Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model Completed NCT01534195 Phase 4 Prednisolone Sodium Phosphate Ophthalmic Solution 1%;Tears Naturale II Ophthalmic Solution
26 A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis Completed NCT01470118 Phase 4 alcaftadine 0.25% ophthalmic solution;olopatadine 0.2% ophthalmic solution;dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
27 Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis Completed NCT01443442 Phase 4 bepotastine besilate, 1.5%;Loteprednol etabonate
28 Tolerability of Grazax in Patients With Hayfever in Real Life Settings Completed NCT01433510 Phase 4 Grazax
29 Patient Perception Study for AL-4943A Completed NCT01294969 Phase 4 AL-4943A
30 Assessment of Alcon's Ocular Image Quantification System Completed NCT01282138 Phase 4 Olopatadine hydrochloride, 0.1% ophthalmic solution (Patanol)
31 A Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic Conjunctivitis Completed NCT01272089 Phase 4 Olopatadine Hydrochloride Ophthalmic Solution, 0.2%
32 Patient Perceptions and Quality of Life Associated With the Use of Olapatadine 0.2% for the Treatment of Allergic Conjunctivitis Completed NCT01159769 Phase 4 Olopatadine hydrochloride ophthalmic solution, 0.2% (Pataday®)
33 Assessing the Efficacy of Maxidex® and Patanol® for the Treatment of Allergic Conjunctivitis Completed NCT01119287 Phase 4 Dexamethasone 0.1% ophthalmic suspension;Olopatadine hydrochloride 0.1% ophthalmic solution
34 Clinical Evaluation of 0.1% Olopatadine Hydrochloride Ophthalmic Solution in Pediatric Patients Completed NCT01109485 Phase 4 Olopatadine hydrochloride ophthalmic solution 0.1%
35 Study of the Effect of Fluticasone Furoate Nasal Spray on Spring Allergy Eye Symptoms Completed NCT00891436 Phase 4 Fluticasone furoate nasal spray;Placebo nasal spray
36 Efficacy Investigation Study of Olopatadine Hydrochloride Ophthalmic Solution Using OHIO Chamber in Patients With Seasonal Allergic Rhinitis (SAR) Completed NCT00818805 Phase 4 Olopatadine 0.1%;Tranilast 0.5%;Placebo (Olopatadine);Placebo (Tranilast)
37 Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model Completed NCT00689078 Phase 4 Prednisolone Acetate 1%;Prednisolone Acetate 0.12%;Loteprednol Etabonate 0.2%;Placebo
38 A Comparison of Olopatadine and Fluticasone in Patients With Allergic Conjunctivitis Completed NCT00655109 Phase 4 Olopatadine;Fluticasone;Saline;Artificial tears
39 Mast-Cell Stabilizing Effects of Olopatadine Completed NCT00389025 Phase 4 Olopatadine (generic name)
40 A Study of the Effects of Desloratadine on Conjunctival Allergen Challenge-induced Ocular Signs and Symptoms (Study P04209) Completed NCT00311844 Phase 4 desloratadine
41 Ketotifen Ophthalmic Solution With Emedastine in Patients With Seasonal Allergic Conjunctivitis Completed NCT00133627 Phase 4 Ketotifen
42 Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis Completed NCT00407043 Phase 4 Lotemax;Restasis
43 A Placebo Controlled Comparison of Topical Zirgan Versus Genteal Gel for the Treatment of Adenovirus Conjunctivitis Completed NCT01533480 Phase 4 Zirgan;genteal gel
44 A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye Completed NCT02117687 Phase 4 carboxymethylcellulose 0.5%/glycerin 0.9%;sodium hyaluronate 0.18%
45 Effect of Lifitegrast on Dry Eye Disease Signs and Symptoms Completed NCT03451396 Phase 4 Lifitegrast
46 Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment Completed NCT00798577 Phase 4 Vigamox Ophthalmic Solution;BSS placebo
47 A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis Completed NCT00464438 Phase 4 gatifloxacin;moxifloxacin 0.5% eye drops
48 Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora Completed NCT00312338 Phase 4 VIGAMOX
49 Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye Completed NCT00987727 Phase 4 carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD);sodium hyaluronate 0.18% (VISMED® Multi)
50 The Utility of IVCM to Assess Cellular Response and Efficacy of Long-term Topical Steroid Treatment in Patients With DED Completed NCT02120079 Phase 4 Lotemax;Soothe Tired Eyes Lubricant Eye Drop (Artificial Tears)

Search NIH Clinical Center for Conjunctival Disease

Cochrane evidence based reviews: conjunctival diseases

Genetic Tests for Conjunctival Disease

Anatomical Context for Conjunctival Disease

MalaCards organs/tissues related to Conjunctival Disease:

42
Eye, Testes, Skin, Bone, Salivary Gland, Thyroid, B Cells

Publications for Conjunctival Disease

Articles related to Conjunctival Disease:

(show all 26)
# Title Authors Year
1
Topical Tacrolimus for Chronic Allergic Conjunctival Disease with and without Atopic Dermatitis. ( 30947551 )
2019
2
Evaluation of Chemokine mRNA Expression to Assess Allergic Inflammation of the Ocular Surface in Chronic Allergic Conjunctival Diseases. ( 30829721 )
2019
3
Clinical Severity and Tear Biomarkers, Eosinophil Cationic Protein and CCL23, in Chronic Allergic Conjunctival Diseases. ( 27929738 )
2018
4
Japanese guidelines for allergic conjunctival diseases 2017. ( 28209324 )
2017
5
Histamine H1 and H4 receptor expression on the ocular surface of patients with chronic allergic conjunctival diseases. ( 28391980 )
2017
6
Age-Related Conjunctival Disease in the C57BL/6.NOD-Aec1Aec2 Mouse Model of Sjögren Syndrome Develops Independent of Lacrimal Dysfunction. ( 25758816 )
2015
7
Skin Prick Test Reactivity to Aeroallergens among Egyptian Patients with Isolated Allergic Conjunctival Disease. ( 28502143 )
2015
8
[Evaluation of the efficacy of subjective symptoms, objective findings, and of a total tear IgE detection kit in diagnosis of allergic conjunctival diseases]. ( 22690539 )
2012
9
Japanese guideline for allergic conjunctival diseases. ( 21636966 )
2011
10
Concentration of soluble interleukin-6 receptors in tears of allergic conjunctival disease patients. ( 17926108 )
2007
11
Evaluation of total and allergen-specific secretory IgA in tears of allergic conjunctival disease patients. ( 17926109 )
2007
12
Roles of T-cells in the development of allergic conjunctival diseases. ( 17881914 )
2007
13
Elevated levels of human alpha -defensin in tears of patients with allergic conjunctival disease complicated by corneal lesions: detection by SELDI ProteinChip system and quantification. ( 16123017 )
2005
14
Evaluation of ocular surface inflammation in the presence of dry eye and allergic conjunctival disease. ( 17216110 )
2005
15
Predominance of infiltrating IL-4-producing T cells in conjunctiva of patients with allergic conjunctival disease. ( 15590468 )
2004
16
Tarsal-conjunctival disease associated with Wegener's granulomatosis. ( 13129876 )
2003
17
Tear osteopontin levels in patients with allergic conjunctival diseases. ( 12486515 )
2002
18
[Topical Fk506 in inflammatory corneal and conjunctival diseases. A pilot study]. ( 11987039 )
2002
19
Histamine release test and measurement of antigen-specific IgE antibody in the diagnosis of allergic conjunctival diseases. ( 11291108 )
2001
20
Penetrating keratoplasty in cicatrizing conjunctival diseases. ( 7724175 )
1995
21
Impression Cytology with Transfer in xerophthalmia and conjunctival diseases. ( 1490836 )
1992
22
Alpha-1 antitrypsin and serum albumin levels in tear fluid of healthy subjects and in persons with conjunctival diseases. ( 3267008 )
1988
23
Immunoassay of tear lysozyme in conjunctival diseases. ( 6812619 )
1982
24
Feline ophthalmologic diseases. Conjunctival diseases. ( 6276707 )
1981
25
Diagnostic cytology in some conjunctival diseases. ( 1031082 )
1976
26
Silver preparations in conjunctival disease. ( 16692078 )
1906

Variations for Conjunctival Disease

Expression for Conjunctival Disease

Search GEO for disease gene expression data for Conjunctival Disease.

Pathways for Conjunctival Disease

Pathways related to Conjunctival Disease according to GeneCards Suite gene sharing:

(show all 25)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.84 CCL11 IFNA2 IL13 IL4 IL5 IL6ST
2
Show member pathways
13.21 CCL11 IFNA2 IL13 IL4 IL5 IL6ST
3 12.63 IFNA2 IL13 IL4 IL5 IL6ST
4
Show member pathways
12.43 IL13 IL4 IL5 IL6ST
5
Show member pathways
12.41 IL13 IL4 IL5 MS4A2
6
Show member pathways
12.24 CCL11 IFNA2 IL13 IL4 IL5 MS4A2
7
Show member pathways
12.17 IFNA2 IL13 IL4 IL5 IL6ST
8
Show member pathways
12.09 IFNA2 IL13 IL4 IL5
9
Show member pathways
11.99 CCL11 IL13 IL4 IL5 IL6ST
10
Show member pathways
11.93 CCL11 IL13 IL4 IL5
11
Show member pathways
11.88 IL13 IL4 PLG
12 11.81 IFNA2 IL4 IL5
13 11.79 CCL11 IL13 IL4
14 11.63 IL13 IL4 IL5
15 11.6 IL13 IL4 IL5
16 11.52 CCL11 IL13 IL4
17 11.45 CCL11 IL4 IL5
18 11.26 CCL11 IL13 IL4 IL5
19 11.11 IL13 IL4 IL5
20 11.01 IL13 IL4 IL5
21 10.99 CCL11 IL13 IL4 IL5
22 10.98 PLG PSEN2
23 10.91 IL13 IL4 IL5
24 10.88 CCL11 IL6ST
25 10.59 CCL11 IL13 IL4 IL5

GO Terms for Conjunctival Disease

Cellular components related to Conjunctival Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.5 CCL11 IFNA2 IL13 IL4 IL5 PLG
2 extracellular region GO:0005576 9.28 CCL11 IFNA2 IL13 IL4 IL5 IL6ST

Biological processes related to Conjunctival Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.8 CCL11 IL13 IL4 IL5 MS4A2
2 regulation of signaling receptor activity GO:0010469 9.77 CCL11 IFNA2 IL13 IL4 IL5
3 positive regulation of B cell proliferation GO:0030890 9.5 IL13 IL4 IL5
4 eosinophil chemotaxis GO:0048245 9.46 CCL11 HRH1
5 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.46 IFNA2 IL13 IL4 IL6ST
6 positive regulation of interleukin-13 production GO:0032736 9.43 IL4 NLRP3
7 cytokine-mediated signaling pathway GO:0019221 9.43 CCL11 IFNA2 IL13 IL4 IL5 IL6ST
8 negative regulation of complement-dependent cytotoxicity GO:1903660 9.26 IL13 IL4
9 inflammatory response GO:0006954 9.17 CCL11 HRH1 IFNA2 IL13 IL5 MS4A2

Molecular functions related to Conjunctival Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine receptor binding GO:0005126 9.13 IFNA2 IL13 IL4
2 cytokine activity GO:0005125 9.02 CCL11 IFNA2 IL13 IL4 IL5

Sources for Conjunctival Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....